TargetBeta
IL10
interleukin 10 · also CSIF, TGIF, IL10A, IL-10 · Interleukins
1 program in company-led studies act on IL10, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| XT-150rule | Xalud Therapeutics | phase 2 | 81 running | – | the studies' text |
Conditions their studies are in
- Amyotrophic Lateral Sclerosis, 1 program
- Back Pain, 1 program
- Neuralgia, 1 program
- Osteoarthritis, 1 program
- Osteoarthritis, Knee, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 2028XT-150 · Xalud Therapeutics · phase 2 · NCT06704347
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.